Cargando…

Inflammation-related plasma and CSF biomarkers for multiple sclerosis

Effective biomarkers for multiple sclerosis diagnosis, assessment of prognosis, and treatment responses, in particular those measurable in blood, are largely lacking. We have investigated a broad set of protein biomarkers in cerebrospinal fluid (CSF) and plasma using a highly sensitive proteomic imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jesse, Khademi, Mohsen, Fugger, Lars, Lindhe, Örjan, Novakova, Lenka, Axelsson, Markus, Malmeström, Clas, Constantinescu, Clara, Lycke, Jan, Piehl, Fredrik, Olsson, Tomas, Kockum, Ingrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2020
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293699/ https://www.ncbi.nlm.nih.gov/pubmed/32457139 http://dx.doi.org/10.1073/pnas.1912839117

Ejemplares similares

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers
por: Huang, Jesse, et al.
Publicado: (2021)

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
por: Sandgren, Sofia, et al.
Publicado: (2023)

Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers
por: Novakova, Lenka, et al.
Publicado: (2018)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis
por: Singh, Avadhesh Kumar, et al.
Publicado: (2017)

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)
por: Jernås, Margareta, et al.
Publicado: (2013)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis
por: Bergman, Petra, et al.
Publicado: (2016)

The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis
por: Iacobaeus, Ellen, et al.
Publicado: (2011)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

SARS‐COV‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder
por: Johnsson, Magnus, et al.
Publicado: (2022)

Smoking Attributable Risk in Multiple Sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2022)

Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
por: Smith, Kelsi A, et al.
Publicado: (2023)

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
por: Rosenstein, Igal, et al.
Publicado: (2021)

Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2023)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
por: Delcoigne, Bénédicte, et al.
Publicado: (2020)

Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology
por: Zheleznyakova, Galina Yurevna, et al.
Publicado: (2021)

Neuronal antibodies in adult patients with new‐onset seizures: A prospective study
por: Zelano, Johan, et al.
Publicado: (2019)

Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression
por: Christensen, Jeppe Romme, et al.
Publicado: (2013)

Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression
por: Romme Christensen, Jeppe, et al.
Publicado: (2013)

Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis
por: Åkesson, Julia, et al.
Publicado: (2023)

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1
por: Wasling, Pontus, et al.
Publicado: (2019)

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

GM-CSF and CXCR4 Define a T Helper Cell Signature in Multiple Sclerosis
por: Galli, Edoardo, et al.
Publicado: (2019)

The DQB1(*)03:02 Genotype and Treatment for Pain in People With and Without Multiple Sclerosis
por: Burkill, Sarah, et al.
Publicado: (2020)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients
por: Fernandes, Sunjay Jude, et al.
Publicado: (2019)

Absence of systemic oxidative stress and increased CSF prostaglandin F(2α) in progressive MS
por: Lam, Magda A., et al.
Publicado: (2016)

Low sun exposure increases multiple sclerosis risk both directly and indirectly
por: Hedström, Anna Karin, et al.
Publicado: (2019)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis
por: Birkeldh, Ulrika, et al.
Publicado: (2017)

Smoking and Epstein–Barr virus infection in multiple sclerosis development
por: Hedström, Anna Karin, et al.
Publicado: (2020)

B‐cell repopulation dynamics and drug pharmacokinetics impact SARS‐CoV‐2 vaccine efficacy in anti‐CD20‐treated multiple sclerosis patients
por: Asplund Högelin, Klara, et al.
Publicado: (2022)

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
por: Al Nimer, Faiez, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t6p49g9vc1fesqnc6u55396401